{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T12:45:31Z","timestamp":1648903531367},"reference-count":37,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.3892\/etm.2014.1974","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T08:15:21Z","timestamp":1410941721000},"page":"1585-1592","source":"Crossref","is-referenced-by-count":8,"title":["Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis"],"prefix":"10.3892","volume":"8","author":[{"given":"YA-FEI","family":"LIU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HUI","family":"DONG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHENG-HAO","family":"TU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CUI-HONG","family":"ZHENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PEI-LIN","family":"LIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YONG-HONG","family":"HU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2014,9,17]]},"reference":[{"key":"key20180108130749_b1-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"key20180108130749_b2-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00296-002-0237-4","article-title":"Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis","volume":"23","author":"Feldtkeller","year":"2003","journal-title":"Rheumatol Int"},{"key":"key20180108130749_b3-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/14728214.7.2.235","article-title":"Anti-TNF agents for the treatment of spondyloarthropathies","volume":"7","author":"Sieper","year":"2002","journal-title":"Expert Opin Emerg Drugs"},{"key":"key20180108130749_b4-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/33.10.927","article-title":"Serum cytokines (IL-6, TNF-\u03b1, IL-1\u03b2 and IFN-\u03b3) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity","volume":"33","author":"Gratacos","year":"1994","journal-title":"Rheumatology"},{"key":"key20180108130749_b5-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","article-title":"Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis","volume":"38","author":"Braun","year":"1995","journal-title":"Arthritis Rheum"},{"key":"key20180108130749_b6-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2165\/00003495-200262170-00013","article-title":"Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis","volume":"62","author":"Culy","year":"2002","journal-title":"Drugs"},{"key":"key20180108130749_b7-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"key20180108130749_b8-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"key20180108130749_b9-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20180108130749_b10-etm-08-05-1585","first-page":"CD004800","article-title":"Sulfasalazine for ankylosing spondylitis","volume":"18","author":"Chen","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"key20180108130749_b11-etm-08-05-1585","first-page":"1482","article-title":"Meta-analysis of sulfasalazine in ankylosing spondylitis","volume":"17","author":"Ferraz","year":"1990","journal-title":"J Rheumatol"},{"key":"key20180108130749_b12-etm-08-05-1585","first-page":"423","article-title":"Efficacy and safety of etanercept for patients with ankylosing spondylitis: a systematic review","volume":"9","author":"Li","year":"2009","journal-title":"Chinese Journal of Evidence-Based Medicine"},{"key":"key20180108130749_b13-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"key20180108130749_b14-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"key20180108130749_b15-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"key20180108130749_b16-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key20180108130749_b17-etm-08-05-1585","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"key20180108130749_b18-etm-08-05-1585","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"key20180108130749_b19-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/ard.2010.139261","article-title":"Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE)","volume":"70","author":"Dougados","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20180108130749_b20-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00296-009-0958-8","article-title":"Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment","volume":"30","author":"Lin","year":"2010","journal-title":"Rheumatol Int"},{"key":"key20180108130749_b21-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor \u03b1","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"key20180108130749_b22-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key20180108130749_b23-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20180108130749_b24-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key20180108130749_b25-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis","volume":"65","author":"van der Heijde","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key20180108130749_b26-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key20180108130749_b27-etm-08-05-1585","first-page":"1043","article-title":"A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept in the treatment of Chinese patients with active ankylosing spondylitis","volume":"50","author":"Huang","year":"2011","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"key20180108130749_b28-etm-08-05-1585","first-page":"741","article-title":"A multicenter, double-blind, placebo-controlled, randomized clinical study of etanercept in the treatment of ankylosing spondylitis","volume":"49","author":"Huang","year":"2010","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"key20180108130749_b29-etm-08-05-1585","first-page":"21","article-title":"Treatment of ankylosing spondylitis with recombinant human tumor necrosis factor-Fc fusion protein (etanercept): a multicenter, randomized, double-blind, placebo-controlled trial","volume":"30","author":"Deng","year":"2009","journal-title":"Jun Yi Jin Xiu Xue Yuan Xue Bao"},{"key":"key20180108130749_b30-etm-08-05-1585","first-page":"1846","article-title":"Efficacy of etanercept in patients with ankylosing spondylitis: A double-blind, randomized, placebo controlled trial","volume":"18","author":"Zhang","year":"2009","journal-title":"Zhongguo Xin Yao Za Zhi"},{"key":"key20180108130749_b31-etm-08-05-1585","first-page":"518","article-title":"Clinical observation of etanercept in treatment of ankylosing spondylitis","volume":"29","author":"Zhao","year":"2009","journal-title":"Suzhou Da Xue Xue Bao"},{"key":"key20180108130749_b32-etm-08-05-1585","first-page":"1506","article-title":"Efficacy of etanercept on ankylosing spondylitis","volume":"29","author":"Zhao","year":"2009","journal-title":"Shanghai Jiaotong Daxue Xuebao Yixueban"},{"key":"key20180108130749_b33-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature","volume":"53","author":"Sterne","year":"2000","journal-title":"J Clin Epidemiol"},{"issue":"Suppl 28","key":"key20180108130749_b34-etm-08-05-1585","first-page":"S111","article-title":"The role of etanercept in ankylosing spondylitis","volume":"20","author":"Davis","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"key20180108130749_b35-etm-08-05-1585","first-page":"913","article-title":"Clinical control study of recombinant human tumor necrosis factor-Fc fusion protein and traditional immunity depressant in treatment of ankylosing spondylitis (AS)","volume":"33","author":"Chen","year":"2010","journal-title":"Xinjiang Yi Ke Da Xue Xue Bao"},{"key":"key20180108130749_b36-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00296-013-2772-6","article-title":"Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis","volume":"33","author":"Machado","year":"2013","journal-title":"Rheumatol Int"},{"key":"key20180108130749_b37-etm-08-05-1585","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00590-012-1035-7","article-title":"Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population","volume":"23","author":"Li","year":"2013","journal-title":"Eur J Orthop Surg Traumatol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/etm.2014.1974\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T03:01:22Z","timestamp":1565838082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2014.1974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,17]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,9,17]]},"published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.3892\/etm.2014.1974"],"URL":"https:\/\/doi.org\/10.3892\/etm.2014.1974","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,17]]}}}